For the year ended June 2026, operating loss was 1,358 million yen, ordinary loss was 1,307 million yen, and net loss attributable to owners of the parent was 1,308 million yen. R&D expenses increased, with CBP501-related costs as the main factor. Cash and cash equivalents decreased to 1,445 million yen. For the year ending June 2027, earnings guidance is not yet determined and depends on the progress of the next-stage clinical trial for CBP501 and the status of partner acquisitions.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4575","jir_company_name":"Canvas Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-12","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4575-20260812-02.pdf","jir_short_summary":"For the year ended June 2026, operating loss was 1,358 million yen, ordinary loss was 1,307 million yen, and net loss attributable to owners of the parent was 1,308 million yen. R&D expenses increased, with CBP501-related costs as the main factor. Cash and cash equivalents decreased to 1,445 million yen. For the year ending June 2027, earnings guidance is not yet determined and depends on the progress of the next-stage clinical trial for CBP501 and the status of partner acquisitions.","jir_summary":"### Overview of Results\nCanvas is a drug discovery company focused on oncology drug development, advancing clinical development centered on CBP501. For the year ended June 2026, operating loss, ordinary loss, and net loss all increased year over year due to rising R&D costs. No partnership was secured, and preparations for the next-stage clinical trial are ongoing. The financial condition shows a notable cash decline, and progress of CBP501's next-stage clinical trial and funding strategy will be key to the earnings outlook.\n\n### Outlook and Cash Flow\nEarnings guidance for the year ending June 2027 has not been published yet and is highly contingent on whether CBP501's next-stage clinical trial starts, the scale of clinical costs, and the presence or absence of upfront payments or cost burdens from collaboration. While there is material uncertainty regarding the going-concern assumption, given the importance of liquidity, the company plans to actively pursue external funding and strategic alliances.","jir_financial_highlights":"Operating loss: \u25b31,358\u767e\u4e07\u5186 (YoY \u25b31,109\u767e\u4e07\u5186)\nOrdinary loss: \u25b31,307\u767e\u4e07\u5186 (YoY \u25b31,156\u767e\u4e07\u5186)\nNet loss: \u25b31,308\u767e\u4e07\u5186 (YoY \u25b31,157\u767e\u4e07\u5186)\nCash and cash equivalents end of period: 1,445\u767e\u4e07\u5186 (decreased from 2,827\u767e\u4e07\u5186 YoY)\nR&D expenses: 1,057\u767e\u4e07\u5186 (increased from prior year)","jir_category":"","jir_hashtags":"#Canvas, #FinancialSummary, #DrugDiscovery, #ImmunoOncology","jir_key_figures":"Operating loss: \u25b31,358,000\u5343\u5186\nOrdinary loss: \u25b31,307,558\u5343\u5186\nNet loss: \u25b31,308,808\u5343\u5186","jir_meta_title":"\u3010Canvas\u3011Financial Summary for the Year Ended June 2026 | Expansion of Drug Discovery Pipeline and Financial Position","jir_meta_description":"Canvas's FY2026 financial results show widening losses due to increased R&D costs. Preparation for CBP501's next-stage clinical trial and external partnership momentum will influence future performance. Focus on funding strategies amid cash decline.","jir_og_title":"Canvas Financial Summary \u2013 Expansion of Drug Discovery Pipeline and Financial Position","jir_og_description":"Summary of CBP501-centered drug development and financial trends. Next year\u2019s guidance is not yet determined; partnerships and funding are key.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58229,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-102973","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n